An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Metastatic Colorectal Cancer
Both
Metastatic Colorectal Cancer
Trial Information
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Inclusion Criteria:
- Measurable disease Tumor available for biopsies. Life expectancy of at least 3
months.
Exclusion Criteria:
- Known or documented brain metastases prior to Cetuximab therapy.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Prediction of response to Erbitux in subjects with metastatic colorectal cancer
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Food and Drug Administration
Study ID:
CA225-045
NCT ID:
NCT00207155
Start Date:
December 2003
Completion Date:
February 2006
Related Keywords:
- Metastatic Colorectal Cancer
- Colorectal Neoplasms
Name | Location |
|---|---|
| Local Institution | Baltimore, Maryland |
| Local Institution | Bronx, New York |
| Local Institution | Cincinnati, Ohio |
| Local Institution | Corona, California |
| Local Institution | Fort Lauderdale, Florida |
| Local Institution | New Brunswick, New Jersey |
| Local Institution | Duncansville, Pennsylvania |
| Local Institution | Austin, Texas |
| Local Institution | Chattanooga, Tennessee |
| Local Institution | Columbia, Missouri |
